Teclistamab stands as a revolutionary cutting-edge anti-BCMA antibody drug construct, designated JNJ-64007957, demonstrating immense efficacy in the therapy of multiple myeloma. This innovative agent operates by https://www.targetmol.com/compound/teclistamab